Products
Trading Strategies
Markets
© 2025 Edgen Powered by
Ask AI About ABM
No Data Yet
Wall Street analysts have issued a series of significant rating adjustments and new initiations across a diverse range of companies, including upgrades for Boeing, Boston Scientific, Chewy, Veeva, and Canada Goose, while Alphabet, TransDigm, SAIC, ABM, and Artelo Biosciences faced downgrades. These recalibrations highlight varying growth prospects, strategic challenges, and evolving market conditions influencing investor sentiment. U.S. equity markets have seen a notable wave of analyst rating adjustments, influencing short-term stock movements and signaling shifts in institutional perspectives across multiple industries. These re-evaluations, encompassing both upgrades and downgrades, reflect a nuanced approach by analysts, focusing on individual company fundamentals, strategic execution, and sector-specific headwinds and tailwinds. Key Upgrades Driven by Operational Strength and Strategic Pivots Boeing (BA) experienced an upgrade from Vertical Research Partners, moving to Buy from Hold with a raised price target of $270. This positive revision is attributed to easing supply chain pressures, stabilizing defense programs, and significant progress in company culture. Vertical Research analyst Robert Stallard noted the aerospace cycle's entry into a 'mid-cycle' phase, with normalized airline traffic growth. Boeing's Q2 2025 results showed a 35% year-over-year revenue surge to $22.75 billion, surpassing analyst expectations, driven by increased commercial aircraft deliveries. The company also improved its core loss per share to -$1.24, better than anticipated. Boston Scientific (BSX) saw its rating lifted to Outperform by Oppenheimer, with a price target of $125. Oppenheimer views Boston Scientific as a premier large-cap Medical Technology (MedTech) growth story, underpinned by disciplined mergers and acquisitions and robust execution, particularly within its electrophysiology franchise. The company reported a 17% year-over-year organic revenue growth and a 23% increase in earnings per share for Q2 2025, demonstrating strong performance and a robust market position. Chewy (CHWY) received an upgrade to Outperform from Mizuho, with a price target adjusted to $50. This upgrade came amidst a recent selloff, with Mizuho identifying a heavily tilted upwards risk/reward profile. The firm anticipates strong upcoming earnings and an optimistic fiscal year 2025 outlook, driven by robust customer growth and expected improvements in core margins. For Q2 2025, Chewy reported revenue of $3.1 billion, an 8.6% increase year-over-year, and earnings per share of $0.33, aligning with analyst forecasts. Veeva Systems Inc. (VEEV) was upgraded to Overweight by JPMorgan, with a price target of $330. The firm highlighted Veeva's substantial penetration opportunity within the $20 billion-plus life sciences industry, noting the company has only captured a fraction of its potential market. JPMorgan projects Veeva to achieve 13% annual revenue growth and maintain cash flow margins exceeding 40% over the next three years, supported by its 'competitively differentiated' platform approach. In Q2 fiscal year 2026, Veeva's total revenues increased by 17% to $789.1 million, with net income rising 17% to $200.3 million. Canada Goose (GOOS) was elevated to a Buy rating from Hold by TD Cowen, with its price target raised to $18. This upgrade primarily reflects the company's strategic pivot towards becoming a year-round lifestyle outerwear brand, moving beyond its traditional winter wear focus. This evolution includes diversification into non-winter categories and enhanced marketing efforts. Shares of Canada Goose saw a significant jump of 11% to 15% following the announcement. For Q1 fiscal year 2026, Canada Goose reported revenue of $108 million, a 22% year-over-year increase, despite an operating loss of $158.7 million. Downgrades Reflect Valuation Concerns and Operational Headwinds Alphabet (GOOGL) saw a downgrade from Phillip Securities, moving to Accumulate from Buy, despite a raised price target of $265. The downgrade was primarily due to valuation concerns following a recent rally in the stock, rather than a negative shift in the company's fundamentals. Phillip Securities maintained a positive view on a U.S. district judge's ruling, which was less severe than anticipated. Alphabet reported consolidated revenues of $96.4 billion in Q2 2025, a 14% increase year-over-year, demonstrating robust momentum. TransDigm Group (TDG) was downgraded by RBC Capital to Sector Perform from Outperform, with a lowered price target of $1,385. The downgrade was attributed to a 'continued period of uncertainty' regarding larger mergers and acquisitions (M&A) and doubts about the aftermarket segment's ability to maintain its outperformance. TransDigm reported Q3 fiscal year 2025 earnings per share of $9.60, slightly below forecasts, and revenue of $2.24 billion, missing expectations. The company also declared a special cash dividend of $90.00 per share, signaling a shift from M&A-driven growth to capital return. Science Applications International Corporation (SAIC) received a downgrade to Neutral from Overweight by J.P. Morgan, with a reduced price target of $115. This decision stems from a weakened revenue outlook and challenges associated with the company's strategic pivot. SAIC's Q2 revenue declined 2.7% year-over-year to $1.77 billion, falling short of analyst expectations, leading to a downward revision of its full-year revenue guidance. ABM Industries (ABM) was downgraded to Neutral from Outperform by Baird, with a lowered price target of $54. The downgrade followed weaker-than-expected profitability in Q3 fiscal year 2025, largely due to margin pressures from contract concessions amidst weak office demand. Despite revenue growth, adjusted earnings per share of $0.82 fell below the consensus estimate of $0.95, and adjusted EBITDA margins contracted. Artelo Biosciences (ARTL) was downgraded to Hold by D. Boral Capital, which also removed its price target. This decision followed an 'unexpected' $3 million capital raise and a 'confusing crypto-related initiative.' The stock plunged over 51% in the preceding week. The small, dilutive capital raise, coupled with its unconventional strategy of allocating a portion of capital to highly volatile digital assets, raised significant investor skepticism, especially for a clinical-stage biotech company with no revenue. New Coverage Initiations Highlight Emerging Themes New analyst coverage also provided fresh insights into emerging and established companies. Bullish (BLSH), an institutionally focused global digital asset platform, was initiated with an Overweight rating by Cantor Fitzgerald, with a price target of $56, signaling bullish sentiment on the growth of institutional digital asset adoption. Duolingo (DUOL) received an Underweight rating from Wells Fargo, with a price target of $239. While acknowledging its strong brand, Wells Fargo expressed caution due to competitive risks, a high valuation, and a slowdown in daily active user growth, anticipating persistent user growth issues. Bakkt Holdings Inc (BKKT) was initiated with a Buy rating by Benchmark, setting a price target of $13. Benchmark views Bakkt as poised for a 'fresh start' following restructuring, divesting non-core operations, and refocusing on brokerage-in-a-box solutions, a multinational bitcoin treasury strategy, and stablecoin payments. Comcast Corp (CMCSA) entered coverage with a Sector Perform recommendation from RBC Capital, at a price target of $38. RBC cited intensified competition from fiber and fixed wireless access providers as primary challenges impacting Comcast's subscriber metrics and market share, noting a lack of near-term catalysts for significant operational shifts despite strong financials. Finally, BioMarin Pharmaceutical (BMRN) was initiated with a Neutral recommendation by H.C. Wainwright & Co., with a price target of $60. BioMarin, a global biotechnology company focused on therapies for rare genetic diseases, has eight approved therapies and projects annual revenue growth of over 21%. Broader Context and Market Implications These diverse analyst actions underscore a market that is increasingly selective, rewarding companies demonstrating clear growth trajectories, operational efficiencies, and strategic adaptability, while penalizing those facing significant execution challenges or unconventional financial strategies. The aerospace sector, exemplified by Boeing's upgrade, appears poised for continued recovery as supply chain issues ease and travel demand normalizes. In the MedTech space, Boston Scientific's upgrade highlights the resilience and growth potential of companies with strong innovation and strategic M&A. Conversely, the downgrades of companies like SAIC and ABM reflect broader economic pressures. SAIC's struggles with a weakened revenue outlook and strategic pivot highlight the difficulties government contractors face in a fluctuating spending environment. ABM's margin compression, stemming from weak office demand, illustrates the ongoing challenges within sectors tied to commercial real estate. The market's reaction to Artelo Biosciences' capital raise and crypto strategy serves as a cautionary tale regarding unconventional financing and the potential for significant investor skepticism when such strategies are not core to a company's fundamental business model, especially for early-stage, revenue-less entities. The new initiations point to emerging areas of interest. The coverage of Bullish and Bakkt signals increasing institutional attention on the digital asset space, albeit with varying degrees of optimism reflecting the inherent volatility and evolving nature of the sector. The measured outlook for Duolingo and Comcast suggests that even well-established players face significant competitive pressures and the need for continuous innovation to sustain growth in rapidly changing industries. Expert Commentary Analyst perspectives reinforce the analytical rigor underpinning these rating changes. Robert Stallard of Vertical Research, in upgrading Boeing, observed that the aerospace cycle has entered what could be considered the 'mid-cycle,' implying a more balanced industry outlook. > "We view the overall ruling positively and believe restrictions on exclusivity have limited impacts on GOOGL given product strength and partner incentives," noted Phillip Securities regarding Alphabet's legal outcome, even as they downgraded the stock on valuation. On the challenges faced by SAIC, CEO Toni Townes-Whitley acknowledged the market's volatility, stating, "We have all acknowledged the volatility in the market over the last few quarters with changes of fundamental reduction in the government personnel..." This highlights the macro challenges impacting government contractors. Andrew Wittmann of Baird, commenting on ABM's situation, noted that while the company's strategic move to accept lower pricing for longer contract terms was reasonable for client protection, it ultimately 'undermined earnings momentum,' pointing to the delicate balance between client retention and profitability in a competitive market. Looking Ahead The coming weeks will likely see continued market scrutiny on corporate earnings reports, particularly from companies like Chewy, whose upcoming results are highly anticipated to alleviate investor concerns. The success of strategic pivots by companies such as Canada Goose, SAIC, and Bakkt will be crucial in validating analyst outlooks and influencing long-term investor confidence. Furthermore, macroeconomic indicators, including inflation data and interest rate decisions, will continue to shape investor sentiment and impact sectors sensitive to consumer spending and borrowing costs. Developments in regulatory environments, as seen with Alphabet, will also remain a key factor for major technology companies. For companies like Artelo Biosciences, the market will be closely watching for clearer operational consistency and the outcomes of their core clinical trials to outweigh concerns about unconventional financial strategies.
Wall Street analysts have issued significant upgrades for Boeing, Boston Scientific, and Chewy, citing improving fundamentals and growth prospects. Conversely, major firms like Alphabet and TransDigm faced downgrades due to valuation concerns and strategic uncertainties, influencing market sentiment across these diverse sectors. Market Overview: Analyst Actions Drive Sector-Specific Movements U.S. equities experienced varied movements following a series of significant analyst rating adjustments across several key companies. While the broader market, including indices like the S&P 500, reflected a mixed sentiment, individual stock performances were notably influenced by these revised outlooks. The actions underscored a re-evaluation of long-term investment theses, driven by factors ranging from operational improvements and strategic execution to valuation concerns and shifts in industry dynamics. Key Analyst Calls and Their Rationale Recent analyst activity saw prominent upgrades and downgrades impacting major players across the aerospace, medical technology, e-commerce, and technology sectors. These shifts were accompanied by detailed rationales and revised price targets, providing investors with new perspectives on corporate valuations and future growth trajectories. Boeing (BA) Soars on Operational Improvements and Cultural Shift Boeing (BA) received a notable upgrade from Vertical Research, moving its rating to Buy from Hold, with a revised price target of $270, up from $242. This positive reassessment stemmed from easing supply chain pressures, stabilization within defense programs, and a perceived positive shift in the company's leadership tone and culture. Analyst Robert Stallard highlighted that the aerospace cycle has entered a "mid-cycle" phase, characterized by normalizing airline traffic growth and improved production flow at Boeing's commercial aircraft unit. The ongoing acquisition of Spirit AeroSystems (SPR) is anticipated to further bolster internal production capabilities. Financially, Vertical Research forecasts an adjusted loss of $2.36 per share for Boeing in 2025, transitioning to adjusted earnings of $2.86 per share in 2026. Free cash flow is also projected to swing from a $3 billion outflow in 2025 to a $4.7 billion inflow in 2026. This optimism is echoed by UBS, which maintains a Buy rating and a $280.00 price target. Boston Scientific (BSX) Recognized for Growth and Execution Boston Scientific (BSX) saw its rating upgraded by Oppenheimer to Outperform from Perform, accompanied by an increased price target of $125, up from $118. Oppenheimer cited the medical device company as "one of the best large-cap MedTech growth stories," attributing the upgrade to its disciplined merger and acquisition strategy and strong execution, particularly within its electrophysiology franchise. The company has demonstrated robust financial performance, with a 21.4% revenue growth over the last twelve months. For the second quarter of 2025, Boston Scientific reported a 17% year-over-year organic revenue growth and a 23% increase in earnings per share. The new price target of $125 represents approximately 52 times the forward price-to-earnings (P/E) ratio, notably higher than the large-cap medical technology sector's average P/E of about 30 times. The firm anticipates Boston Scientific to achieve an 11-13% compound annual growth rate (CAGR), outpacing the broader large-cap medical technology sector's estimated 8% growth rate. Chewy (CHWY) Gains Momentum on Improved Outlook Chewy Inc. (CHWY) received an upgrade from Mizuho to Outperform from Neutral, with a price target increase to $50 from $44. This upgrade reflects a renewed optimism, driven by an attractive risk/reward profile following a recent selloff. Mizuho anticipates a strong upcoming earnings report and fiscal 2025 outlook, citing robust customer growth—with net additions exceeding 100,000 per quarter—and an expected improvement in core margins. In the first quarter, Chewy reported net sales of $3.12 billion, an 8.3% year-over-year increase, surpassing analyst expectations. Adjusted EPS for Q1 came in at $0.35, significantly exceeding consensus estimates. Autoship sales, a significant strength for the company, were up 14.8% year-over-year to $2.56 billion, accounting for 82.2% of total net sales. Chewy holds approximately a 33% market share in the online pet category, with further growth potential as the U.S. pet category continues its transition to digital platforms. Alphabet (GOOGL) Faces Valuation-Based Downgrade Alphabet Inc. Class A (GOOGL) experienced a downgrade from Phillip Securities to Accumulate from Buy. While the firm views a recent U.S. district judge ruling positively—believing restrictions on exclusivity will have limited impact on Google's product strength—the downgrade was primarily driven by valuation concerns following the stock's recent rally. Despite the downgrade, the price target was raised to $265 from $235, reflecting the perceived underlying strength. In Q2 2025, Alphabet's consolidated revenues increased 14% to $96.4 billion, with strong performance across Google Search, YouTube ads, and Google Cloud. Operating income also increased 14%, with an operating margin of 32.4%. Analysts expect Alphabet to continue benefiting from AI-driven product enhancements and operational efficiencies, despite the re-evaluation of its immediate upside due to its current valuation. TransDigm (TDG) Downgraded Amidst M&A Uncertainty TransDigm Group (TDG) was downgraded by RBC Capital from Outperform to Sector Perform, with its price target reduced to $1,385 from $1,550. The aerospace component manufacturer, currently trading near its 52-week low, faced the downgrade due to a "continued period of uncertainty" concerning the outlook for larger mergers and acquisitions (M&A) heading into fiscal year 2026. RBC also expressed doubt regarding the aftermarket segment's ability to sustain its outperformance as the industry normalizes. TransDigm's third-quarter earnings for fiscal year 2025 fell short of analyst expectations, with earnings per share (EPS) of $9.60 missing the forecasted $9.86, and revenue of $2.24 billion falling below the anticipated $2.29 billion. The company's recent $5 billion debt issuance, used for a special dividend rather than a buyout, signals a potential pivot from TransDigm's usual M&A-heavy strategy, contributing to the cautious outlook. Broader Context and Implications These analyst actions highlight the nuanced factors driving market sentiment. For the aerospace sector, represented by Boeing, the easing of supply chain constraints and a focus on operational efficiency signal a robust recovery and growth phase. The medical technology sector, exemplified by Boston Scientific, continues to demonstrate strong growth potential driven by strategic acquisitions and innovation. In contrast, the technology and industrial sectors are seeing a recalibration of valuations, with market participants scrutinizing growth catalysts and M&A strategies more closely. Analyst Robert Stallard's commentary on the aerospace sector provides a key insight into the current environment: > "To us, this suggests adopting a more balanced aero aftermarket versus OEM stance, and so we are upgrading one of the most prominent OEM names." This underscores a broader industry trend where fundamental operational improvements and strategic clarity are increasingly valued. Similarly, the re-rating of companies like Alphabet based on valuation, despite strong underlying performance, indicates a market adjusting its expectations for even high-growth stocks in a dynamic economic landscape. The shift in TransDigm's M&A strategy could also signify a broader trend in the aerospace and defense sector towards disciplined capital management over aggressive consolidation. Looking Ahead Investors will closely monitor upcoming earnings reports and company guidance for further validation of these analyst adjustments. For Boston Scientific, the upcoming Investor Day on September 30, 2025, will likely provide additional insights into its long-term strategy and growth drivers. The aerospace sector will be watching for continued improvements in supply chain stability and any updates on regulatory decisions, such as the Federal Aviation Administration's (FAA) stance on Boeing's 737 MAX production cap. The evolving landscape of AI integration and its impact on revenue streams will remain a critical focus for Alphabet and other technology giants. For TransDigm, future clarity on its capital allocation strategy and potential M&A activities will be key determinants of investor confidence. These individual company narratives, shaped by analyst perspectives, will collectively contribute to the overall direction of the market in the coming weeks.
The P/E ratio of ABM Industries Inc is 34.1827
Mr. Scott Salmirs is the President of ABM Industries Inc, joining the firm since 2015.
The current price of ABM is $45.5, it has increased 0.02% in the last trading day.
ABM Industries Inc belongs to Commercial Services & Supplies industry and the sector is Industrials
ABM Industries Inc's current market cap is $2.8B
According to wall street analysts, 6 analysts have made analyst ratings for ABM Industries Inc, including 3 strong buy, 4 buy, 4 hold, 0 sell, and 3 strong sell